Evidence map›Paper›PMID 30140596›Full record

ArticleCureus2018

Effect of High-dose Biotin on Thyroid Function Tests: Case Report and Literature Review.

Arash Ardabilygazir, Sonia Afshariyamchlou, Danial Mir, Issac Sachmechi

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Practical considerations for accurate determination of free thyroxine by equilibrium dialysis.Journal of mass spectrometry and advances in the clinical lab · 2023
    Article
  4. Review
  5. Review
  6. Article
  7. Gut Microbiome Alterations in Patients With Thyroid Nodules.Frontiers in cellular and infection microbiology · 2021
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Arash ArdabilygazirMedicine, Icahn School of Medicine at Mount Sinai Queen Hospital Center, New York, USA.
Sonia AfshariyamchlouMedicine, Icahn School of Medicine at Mount Sinai Queen Hospital Center, New York, USA.
Danial MirMedicine, Icahn School of Medicine at Mount Sinai Queen Hospital Center, New York, USA.
Issac SachmechiInternal Medicine, Icahn School of Medicine at Mount Sinai Queen Hospital Center, New York, USA.
Mount Sinai Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biotin is a readily available supplement that is part of the B-complex vitamins. It is an essential co-factor for five carboxylases involved in fatty acid synthesis and energy production. The recommended daily intake (RDI) of biotin ranges from 30 to 70 mcg per day. At high doses (10,000 times RDI), biotin improves clinical outcomes and quality of life in patients with progressive multiple sclerosis (MS). It has been reported to cause interference in immunoassays resulting in abnormal thyroid function tests. Hereby we are describing the case of a patient having MS who was on high-dose biotin, seen in the clinic for a follow-up visit with thyroid function tests suggestive of Graves' disease with no signs and symptoms of hyperthyroidism and completely normal physical examination. In the case we have described, the laboratory measurements suggestive of thyrotoxicosis were attributed to interference of the patient's high-dose biotin treatment with the biotin-streptavidin chemistry of the immunoassays. We observed normalization of the thyroid stimulating hormone (TSH) and free T4 measurements when the patient withheld biotin for a week. As our case illustrates, early consideration of biotin interference minimizes unnecessary repeat laboratory studies. As trials in MS are progressing, we expect to see more patients on high-dose biotin treatment with spurious laboratory measurements. Therefore, we advise careful history taking and close communication with the laboratory when the clinical picture does not match with the laboratory results.

Indexed as

biotin-streptavidin immunoassaygraves diseasehigh dose biotinhyperthyroidismmultiple sclerosisthyroid function tests

Identifiers

PMID30140596
PMCPMC6103391
OpenAlexW2808762985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.